- Home
- KURA vs DVAX Comparison
KURA vs DVAX Comparison
Compare KURA & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- DVAX
- Stock Information
- Founded
- KURA 2014
- DVAX 1996
- Country
- KURA United States
- DVAX United States
- Employees
- KURA N/A
- DVAX N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- KURA Health Care
- DVAX Health Care
- Exchange
- KURA Nasdaq
- DVAX Nasdaq
- Market Cap
- KURA 1.0B
- DVAX 1.2B
- IPO Year
- KURA N/A
- DVAX 2004
- Fundamental
- Price
- KURA $12.08
- DVAX $11.50
- Analyst Decision
- KURA Buy
- DVAX Buy
- Analyst Count
- KURA 11
- DVAX 4
- Target Price
- KURA $25.00
- DVAX $26.50
- AVG Volume (30 Days)
- KURA 2.2M
- DVAX 1.9M
- Earning Date
- KURA 11-04-2025
- DVAX 11-05-2025
- Dividend Yield
- KURA N/A
- DVAX N/A
- EPS Growth
- KURA N/A
- DVAX N/A
- EPS
- KURA N/A
- DVAX N/A
- Revenue
- KURA $104,029,000.00
- DVAX $330,514,000.00
- Revenue This Year
- KURA $68.63
- DVAX $23.23
- Revenue Next Year
- KURA $141.59
- DVAX $16.57
- P/E Ratio
- KURA N/A
- DVAX N/A
- Revenue Growth
- KURA N/A
- DVAX 26.73
- 52 Week Low
- KURA $5.41
- DVAX $9.20
- 52 Week High
- KURA $12.49
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- KURA 66.94
- DVAX 64.62
- Support Level
- KURA $10.86
- DVAX $10.69
- Resistance Level
- KURA $11.88
- DVAX $11.58
- Average True Range (ATR)
- KURA 0.88
- DVAX 0.34
- MACD
- KURA 0.08
- DVAX 0.03
- Stochastic Oscillator
- KURA 85.86
- DVAX 92.03
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.